Are Menopause Supplements Worth the Price? What a Which? Analysis Shows About Dose, Value and What to Look For Instead (2026)

Not one of the 26 menopause supplements reviewed by UK consumer watchdog Which? in September 2026 contained the right combination of nutrients at appropriate doses to support their use specifically for menopause — yet some cost more than £485 a year, roughly 22 times the price of a 6p-a-day supermarket multivitamin that matched or outperformed them on several key nutrients.

That headline finding, published by Which? on 30 September 2026, cuts through one of the fastest-growing corners of the wellness market. The global menopause supplement market is valued at nearly $17 billion and is expected to reach $25 billion by 2030, driven by women seeking relief from hot flushes, poor sleep, brain fog, and mood changes. The Which? data suggests much of that spending is not translating into meaningful nutritional benefit.

How the Products Compared: Price, Dose, and Key Nutrients

The table below summarises the products Which? highlighted, alongside the benchmark supermarket multivitamin and NHS/EFSA recommended daily amounts for the three most critical menopause nutrients. Data sourced from the Which? investigation and Vitafoods Insights reporting.

Product	Daily cost	Annual cost	Vitamin D	Calcium	Magnesium	Which? verdict
NHS/EFSA recommended range	—	—	10–15 µg	700–1,000 mg	270–300 mg	—
Asda A-Z Multivitamins & Minerals	6p	£22	10 µg ✓	200 mg	100 mg	Benchmark value pick
Vitabiotics Menopace Max	93p	£340	10 µg ✓	700 mg ✓	100 mg	Highest-scoring menopause product
Health & Her Menopause Multi Nutrient	59p	~£215	0 µg ✗	0 mg ✗	57 mg ✗	Missing key nutrients; over-claimed
MyVitamins Menosure	63p	~£230	Severely underdosed	Severely underdosed	Severely underdosed	Every ingredient fairy-dusted
Wild Nutrition Women's 45+ Daily Multi Nutrient	£1.27	£468	1.5 µg ✗	60 mg ✗	30 mg ✗	Far below recommended levels
Love Mushrooms help	£1.33	£485	Not specified	0 mg ✗	0 mg ✗	No calcium or magnesium; lion's mane underdosed

The pattern is stark: price correlates almost inversely with compliance to recommended nutrient levels. The cheapest option in the table — the Asda multivitamin — meets the vitamin D target and provides more vitamin C (80 mg) than even the highest-scoring menopause-specific product, Vitabiotics Menopace Max (45 mg).

What Did Which? Actually Study, and How Rigorous Was the Analysis?

The Which? investigation is a structured consumer research review, not a randomised controlled trial. Lead researcher Shefalee Loth, a public health nutritionist with more than 20 years at Which? and the NHS, and consultant dietitian Sophie Medlin examined 26 supplements sold at major UK retailers including Holland & Barrett, Boots, and Amazon. They cross-referenced the label content of more than 78 active ingredients against current NHS guidance, European Food Safety Authority (EFSA) dietary reference values, and the peer-reviewed evidence base for each ingredient.

The scope is meaningful. No single ingredient appeared in every supplement reviewed — which itself signals the absence of scientific consensus on what a menopause supplement should contain. A 2026 UCL study of 201 UK-sold supplements reached a similar conclusion, finding that fewer than half of products contained vitamin D and calcium, and that the majority of ingredients were not specifically recommended by major menopause societies.

Dr Xand van Tulleken, an honorary associate professor at the UCL Institute for Global Health, was direct: "Every year our annual spending on menopause supplements is hundreds of times more than our spending on menopause research. There is no persuasive evidence that menopause supplements have a significant effect on women's symptoms, some of them are dangerous, and the pricing and marketing is exploitative and confusing."

Why Are Calcium and Vitamin D So Critical During Menopause?

Calcium and vitamin D are the two most important nutrients for women during perimenopause and menopause because of the direct relationship between oestrogen decline and bone density loss. Oestrogen matters for calcium absorption and for maintaining the rate at which bone is rebuilt. As oestrogen levels fall, bone breaks down faster than it repairs, increasing susceptibility to osteoporosis and fractures.

The British Dietetic Association recommends calcium intake increase from 700 mg per day to 1,200 mg per day for women around menopause. EFSA's dietary reference values for vitamin D sit at 10–15 µg per day for this demographic. Yet the Which? review found that calcium and vitamin D were "often present in token doses in menopause supplements — if at all."

Cleveland Clinic menopause specialist Dr Pelin Batur reinforces this from a clinical standpoint: "Dietary calcium is preferable to supplements whenever possible, but if you have gastrointestinal issues or lactose intolerance, you may not be able to get adequate dietary calcium." She recommends a target of 1,000 to 1,200 mg of calcium per day depending on age, and cautions that vitamin D supplementation should generally stay at or below 2,000 international units to avoid hypercalcaemia.

Magnesium, iron, B vitamins, iodine, selenium, zinc, and vitamins C, E, and K round out the nutrient profile most relevant to menopause. Most branded supplements in the Which? data failed to deliver meaningful doses of even the top two, let alone the full supporting cast.

What Is "Fairy-Dusting" and Why Does It Matter?

"Fairy-dusting" is the practice of including an ingredient on a supplement label at a dose too low to produce any measurable physiological effect — enough to appear on the label and in marketing copy, but not enough to do anything useful. The term has been in use among nutritionists and regulators for years; the Which? investigation applied it systematically across a product category for the first time at this scale.

MyVitamins Menosure is the clearest example in the Which? data. At 63p per daily dose, it sounds affordable — but every vitamin, mineral, and botanical ingredient is severely underdosed according to Which?'s standards. It contains 100 mg of evening primrose oil when the recommended dose is 500 mg. It includes B vitamins with some evidence for menopause support (B12, niacin, folic acid) alongside others — B1, B2, and B7 — for which there is no specific menopause evidence at all.

A MyVitamins spokesperson responded that the product is "a multi-ingredient formulation, so individual ingredients are not intended to be used at the same levels as they would be in a standalone supplement." This is a common industry defence, but it does not resolve the core problem: if no individual ingredient reaches an effective dose, the combined product cannot be expected to deliver meaningful benefit.

Health & Her Menopause Multi Nutrient Supplement (59p per day) carried on-pack claims about cognitive function, energy levels, and even testosterone — yet contains no vitamin D or calcium, while the 57 mg magnesium content is too low to be beneficial. The product includes botanicals such as red clover and sage, but these are also underdosed. Health & Her told Vitafoods Insights that it worked with data scientists at the University of South Wales and Swansea University using anonymised data from over 50,000 women, and that "supplement quality should be judged on more than the milligram amounts on a label." The company also argued that calcium is excluded because most UK women obtain sufficient amounts from their diet.

That rationale may be defensible in isolation, but it sits awkwardly alongside the product's broad health claims and premium price point.

Do Botanical Ingredients Like Black Cohosh or Red Clover Actually Work?

The evidence for botanical ingredients in menopause supplements is mixed at best, and absent or contradictory at worst. The most commonly appearing botanicals in the Which? review were black cohosh, isoflavones (from soy and red clover), ashwagandha, and St John's Wort.

Some research suggests these can help relieve bothersome symptoms such as night sweats and hot flushes. Red clover isoflavones, for instance, appear in Vitabiotics Menopace Max, and research suggests they may be beneficial for hot flushes. But a gold-standard Cochrane systematic review of black cohosh found it had no effect on menopause symptoms.

The problem is compounded by the nature of botanical research. Plants vary in potency between batches, making it harder to standardise doses and replicate trial results. There are also no established reference levels for botanicals' use in menopause in the UK or EU, meaning brands can include them at any dose and make no specific claims — or, in some cases, make broad wellness claims that skirt regulatory boundaries.

Safety is a genuine concern that often gets lost in the "natural equals safe" assumption. Cleveland Clinic's Dr Batur warns explicitly that "supplements are unregulated and can cause serious health problems, like liver toxicity." Rare but documented cases of liver damage have been associated with both black cohosh and ashwagandha. Less severe side effects — stomach upsets, headaches, dizziness — are more common. Botanical ingredients can also interact with prescription medications, which is particularly relevant for women in their 40s and 50s who may be managing other health conditions.

Love Mushrooms' help, the most expensive product in the Which? review at £1.33 a day (£485.45 annually), includes lion's mane extract — an ingredient with some evidence for menopausal mood symptoms and brain fog. But the dose is too low to be effective, according to Which?. Love Mushrooms founder Smith Feeney explained that effective doses of calcium and magnesium "require significant physical volume, including them would force consumers to take multiple extra capsules a day" — a practical constraint, but one that still leaves the product short of menopause-specific nutritional targets.

What Is "Menowashing" and How Does It Inflate Prices?

"Menowashing" is the practice of rebranding existing supplements — or formulating new ones with minimal clinical evidence — specifically for the menopause market, typically at a significant price premium. The term is the menopause-specific equivalent of "greenwashing" in environmental marketing.

Which? expressed concern that regulators are failing to get a grip on dubious marketing and unchecked claims from supplement companies seeking to cash in on the menopause market, describing the supplements industry as a "wild west" where quasi-medical claims go largely unchallenged.

The Wild Nutrition Women's 45+ Daily Multi Nutrient is a useful case study. At £1.27 a day (£468 annually), it is promoted as "menopause-friendly" on the company's website. Which? found it contains just 1.5 µg of vitamin D, 60 mg of calcium, and 30 mg of magnesium — all dramatically below NHS recommended daily amounts. Wild Nutrition also markets this product as part of a "Menopause Support Trio" package that, when fully assembled, costs £3.19 per day or £1,147.56 per year — and still falls short on calcium and vitamin D.

Menopause specialist Dr Louise Newson, whose work focuses on the long-term health risks of hormone deficiency — including osteoporosis, cardiovascular disease, and dementia — has put the issue plainly: "I don't really care if women spend $120 billion or whatever they're spending, as long as they know what they're taking has no evidence, and it's not going to help their long-term health, and it's just a marketing ploy… But the problem is they don't."

The concern is not only financial. When women spend hundreds of pounds on supplements that don't deliver, they may feel they have "done something" about their symptoms while underlying nutritional deficiencies — and the associated long-term health risks — go unaddressed.

What Should You Actually Look For in a Menopause Supplement?

Which?'s practical recommendation is clear: rather than buying an all-in-one menopause blend, start with a high-quality multivitamin and add targeted supplements only where a specific deficiency or symptom warrants it. This approach is likely to be cheaper and more effective.

When evaluating any supplement — menopause-branded or otherwise — the following criteria are worth applying:

Vitamin D dose: Look for at least 10 µg (400 IU) per daily serving, which aligns with NHS guidance for the general population and the lower end of EFSA's range for this demographic. Many menopause supplements provide a fraction of this.

Calcium content: A supplement claiming to support bone health should contain a meaningful calcium dose. Vitabiotics Menopace Max, the highest-scoring product in the Which? review, provides 700 mg — still below the 1,000–1,200 mg target, but closer than anything else reviewed. If a product contains less than 200 mg, it is unlikely to make a material contribution to your daily calcium needs.

Magnesium: The NHS recommends 270–300 mg per day for women in this age group. Products providing 30–57 mg are delivering a token amount.

Botanical ingredients: If a product includes botanicals, check whether the dose matches those used in clinical trials. If the label does not specify the standardised extract and dose, treat the inclusion as decorative rather than functional.

Claims vs. content: Under UK and EU food law, supplements cannot make medicinal claims. If a product implies it will "treat" hot flushes or "cure" brain fog, that is a regulatory red flag. Broad wellness claims ("supports energy," "promotes cognitive function") are legal but tell you nothing about efficacy.

Price per nutrient: Divide the annual cost by the actual nutrient content you are getting. The Asda A-Z multivitamin at £22 per year provides 10 µg of vitamin D and 200 mg of calcium. A £468-per-year product providing 1.5 µg of vitamin D and 60 mg of calcium is not a supplement — it is a marketing exercise.

Cleveland Clinic's guidance aligns with this framework: a healthy lifestyle — balanced diet, exercise, adequate sleep — remains the primary intervention for menopause symptoms, with targeted supplementation as a secondary tool where dietary gaps exist, always under medical supervision.

Is There Any Supplement That Passed the Which? Test?

No product in the Which? review earned a Best Buy designation. The closest was Vitabiotics Menopace Max, which scored highest across the 26 products reviewed. It contains 700 mg of calcium — the only product in the analysis with a genuinely meaningful calcium dose — and includes red clover isoflavones with some clinical evidence for hot flush relief. At 93p per day (£340 per year), it costs more than 15 times the Asda benchmark, and the Asda product still matches it on vitamin D (10 µg) and magnesium (100 mg) while providing more vitamin C (80 mg versus 45 mg).

That is not a ringing endorsement of Menopace Max so much as a reflection of how poorly the rest of the field performed.

Holland & Barrett, whose own-brand menopause products were among those reviewed, responded that its products are "specifically formulated for the nutritional needs associated with this life stage" and contain "meaningful, evidence-based levels of key vitamins and minerals." The Health Food Manufacturers' Association noted that "many life stages, including the menopause, may create increased nutritional demands on an individual and these may be met by supplementation as an addition to a healthy diet."

Both responses are reasonable in principle. The Which? data suggests the execution across the market as a whole falls well short of those stated intentions.

What Does the Broader Research Say About Menopause Supplement Evidence?

The Which? findings do not exist in isolation. A 2026 UCL study examining 201 supplements sold in the UK found that fewer than half contained vitamin D and calcium, and that the majority of ingredients were not specifically recommended by major menopause societies. The UCL researchers called for substantially more investment in menopause supplement research — a call that shows how thin the evidence base currently is.

The Cochrane Library's systematic review of black cohosh, one of the most widely used botanical ingredients in menopause supplements, found no effect on menopause symptoms — a finding that should give pause to anyone paying a premium for a product that leads with this ingredient.

The data on isoflavones (from soy and red clover) is more nuanced. Some trials show modest benefits for vasomotor symptoms like hot flushes; others show no effect. The variability likely reflects differences in the form of isoflavone used, the dose, and individual differences in gut microbiome composition that affect how isoflavones are metabolised.

Ground flaxseed — not a supplement, but a food — has mixed evidence for hot flushes, though it offers broader health benefits as a source of omega-3 fatty acids and fibre. Cleveland Clinic notes that flaxseed's benefits are better realised in ground food form than in supplement capsules.

The honest summary: the evidence base for menopause-specific supplements is thin, inconsistent, and frequently confounded by poor study design and proprietary formulations that make replication difficult. That does not mean no supplement can ever help — it means the burden of proof has not been met for most of what is currently on the market at premium prices.

What Are the Regulatory Gaps Enabling This Market?

Which? described the supplements industry as a "wild west," and the regulatory picture supports that characterisation. In the UK and EU, food supplements are not required to demonstrate efficacy before going to market. Manufacturers must ensure safety and cannot make medicinal claims, but the bar for what constitutes an acceptable "nutrition or health claim" is broad enough to accommodate a great deal of marketing language that implies therapeutic benefit without technically asserting it.

There are no established reference levels for botanical ingredients' use in menopause in the UK or EU, meaning brands can include them at any dose without regulatory challenge. The Advertising Standards Authority and the Medicines and Healthcare products Regulatory Agency (MHRA) can act on specific misleading claims, but proactive surveillance of the supplement market is limited.

Which? has called for regulators to take a more active role in scrutinising marketing claims in the menopause supplement space. The market is projected to reach $25 billion globally by 2030, and the financial incentives for aggressive marketing are only going to intensify.

For consumers, the practical implication is that the label cannot be trusted at face value. The presence of an ingredient on a label does not mean it is present at a dose that does anything. A "menopause-friendly" designation is a marketing choice, not a regulatory standard. A higher price is not a proxy for higher quality — in this market, the Which? data suggests it may be closer to the opposite.

The Bottom Line: How to Spend Your Money More Wisely

The Which? analysis is a useful corrective to a market that has grown faster than the evidence supporting it. For women navigating perimenopause and menopause, the financial and health stakes are real: spending £400–£1,100 per year on supplements that do not deliver adequate doses of the nutrients most needed during this life stage is both a waste of money and a potential missed opportunity to address genuine nutritional gaps.

The practical path forward, based on the available evidence, is straightforward. Start with a quality multivitamin — the Asda A-Z at 6p a day is the Which? benchmark, but any product meeting NHS/EFSA reference values for vitamin D, calcium, and magnesium at a reasonable price qualifies. If bone health is a specific concern, add a targeted calcium supplement to reach the 1,000–1,200 mg daily target, ideally under medical guidance. If hot flushes are severe and persistent, discuss red clover isoflavones or other evidence-supported options with a GP or dietitian before purchasing.

Avoid products that lead with botanical ingredients at undisclosed or sub-therapeutic doses, make broad claims about cognitive function or hormone balance without specifying the mechanism, or charge a premium that cannot be justified by the actual nutrient content on the label.

The menopause supplement market will continue to grow. Whether it matures into a space where products are formulated to genuinely serve women's health needs — rather than their health anxieties — depends on both regulatory pressure and consumer demand for transparency. The Which? investigation is a step toward the latter.

For related reading on evidence-based supplementation approaches, see our guides on what natural supplements help with joint pain and how to evaluate blood pressure supplements.